Pagine dedicate alla Neurologia per l'aggiornamento dei Colleghi e per informazioni sulle nuove terapie e descrizioni di patologie rivolte in modo comprensibile ai pazienti

                                                                                          Dott. Carlo Sebastiano Tadeo
                                                                                                Specialista Neurologia

Terapia dell'ipertensione negli ictus

 

                           Iscrivetevi alle Newsletter                   

                                             Newsletter  

 

 

 Novità dai principali congressi e pubblicazioni scientifiche 

Journals neurology

Per prenotare una visita neurologica

Servizio Traduzione

Medline

Congressi e convegni

Malattie neurologiche

Ictus
Sclerosi Multipla
Alzheimer
Parkinson
Neuropatie ereditarie
Cefalee

 

 

Pubblicità e links utili

 

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.

 

 

www.ilneurologo.com - Candidato al Premio Web Italia 2003

Stroke Patients Show Significant Risk Reduction When Given Atacand (Candesartan Cilexetil)

Sommario: Nuovo studio che definisce chiaramente il beneficio del trattamento dell'ipertensione arteriosa nei pazienti sofferenti di ictus ischemico. I pazienti trattati con Atacand (candesartan cilexetil) (4-16 mg) avevano una mortalità ridotta del 47.5%. Lo studio è stato sospeso dopo aver osservato dei risultati così positivi in 342 pazienti. L'Atacand è un bloccante del recettore angiotensina II tipo 1 (AT1). L'assunzione del farmaco deve essere eseguita entro le prime 72 ore dall'ictus.

BIELEFELD, GERMANY -- November 29, 2001 -- New data investigating the effect of antihypertensive treatment with Atacand (candesartan cilexetil), in acute stroke patients with elevated blood pressure, were presented at the 25th Scientific Meeting of the German Hypertension Society.

The new ACCESS* data clearly define the benefit and safety from early antihypertensive intervention with Atacand for patients suffering from acute ischaemic stroke.

These data reveal that the risk for the combined endpoint of total mortality, cerebral complications and cardiovascular complications, was reduced by 47.5 percent for patients treated with Atacand (4-16 mg) (initiated within 72 hrs post stroke).

"ACCESS is an important new study because it shows Atacand to be the first antihypertensive drug to improve outcomes for acute ischaemic stroke patients with high blood pressure", commented lead investigator Prof. J. Schrader, St.-Josefs-Hospital. "The new data will prove extremely useful, providing guidance to physicians involved with the daily management of patients with acute ischaemic stroke. The safety aspects of early intervention with Atacand were highlighted as an important benefit for this vulnerable patient group."

Stroke is the third leading cause of death in the world today and a leading cause of adult disability. Each year, stroke affects nearly 20 million people worldwide and of these, approximately five million people die. Of the fifteen million people who suffer non-fatal strokes, a third are left disabled, and at least one in six will experience a second stroke within five years.

The final results of the ACCESS study confirm the encouraging preliminary analysis which led to trial recruitment being prematurely stopped with 342 randomised patients (339 valid for statistical evaluation) in March 2001.

Atacand is a selective angiotensin II type 1 (AT1) receptor blocker and is the first antihypertensive therapy to show a benefit with early treatment for acute ischaemic stroke patients with high blood pressure.

References

* The ACCESS study (Acute Candesartan Cilexetil Evaluation in Stroke Survivors) is a double- with 342 randomised patients (339 valid for statistical evaluation) from 53 centres across Germany, looking at the use of Atacand in acute stroke patients with high blood pressure. The objective of the study was to compare the effects of an early (initiated within 72 hrs post stroke) vs. delayed (>7 days post event) antihypertensive treatment with Atacand for this patient population with the primary end point being total mortality and disability after 3 months. Secondary endpoints assessed at 3 and 12 months were a combined criterion of: total mortality, cerebral complications and cardiovascular complications.

* Candesartan cilexetil, is an AT1-receptor blocker which was discovered by Takeda Chemical Industries, Ltd. and has been developed jointly by AstraZeneca and Takeda. The product is now available in most countries under the trade names Atacand and/or Blopress by AstraZeneca and Takeda respectively.

SOURCE: AstraZeneca

 

Per ulteriori informazioni, contattare:

Il Neurologo con voi
Via Copernico 59/a Milano 20125
Tel: 03332699103
Posta elettronica: tadeo@ilneurologo.com

            

Spazio pubblicitario libero

 

Inviare a tadeo@ilneurologo.com un messaggio di posta elettronica contenente domande o commenti su questo sito Web.
Aggiornato il: 02 December 2001